
Product Data Sheet

Product Name: Pareptide monohydrochloride

Cat. No.: GC31211

Chemical Properties

Cas. No. 63236-23-7

SMILES O=C([C@@H]1CCCN1)N(C)[C@H](CC(C)C)C(NCC(N)=O)=O.ClFormula $C_{14}H_{27}ClN_4O_3$ M.Wt 334.84

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Protocol****Animal experiment:**

Mice[1] Male albino mice of a Swiss-Webster derived strain and eighing from 26-34 g are used. Single doses of MIF-I (0.03-2.0 mg/kg, SC) and chronic pretreatments with MIF-I (0,03-2.0 mg/kg, SC, BID, 3.5 days) or Pareptide (0.25 mg/kg, SC, BID, 3.5 days) do not affect the acute cataleptic response to Haloperidol in the mouse. Pareptide is given SC in a 5 mL/kg injection volume. Chronic pretreatment with Haloperidol (8.0 mg/kg, IP, BID, 3 days) decreases the duration of catalepsy in mice given smaller challenge doses of Haloperidol (2.0 or 3.0 mg/kg, IP) 15 hours after the last pretreatment injections. Administration of either MIF-I or Pareptide to mice also chronically pretreated with Haloperidol antagonizes the development of tolerance[1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

References:

[1]. Mycroft FJ, et al. Pro-Leu-Gly-NH₂ and Pareptide inhibit development of tolerance to Haloperidol catalepsy in the mouse. Peptides. 1984 Sep-Oct;5(5):883-7.

Background

Pareptide monohydrochloride is a melanotropin-inhibiting factor (MIF) metabolically stable analogue.

Chronic coadministration of Pareptide (0.25 mg/kg, SC, BID, 3.5 days) to mice pretreated with Haloperidol (8.0 mg/kg, IP, BID, 3 days) significantly increases the cataleptic effects of a smaller challenge dose of Haloperidol (2.0 mg/kg, IP) given 15 hours after the last pretreatment injections ($p < 0.01$)[1].

[1]. Mycroft FJ, et al. Pro-Leu-Gly-NH₂ and Pareptide inhibit development of tolerance to Haloperidol catalepsy in the mouse. Peptides. 1984 Sep-Oct;5(5):883-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA